Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine

Zosano Pharma (NASDAQ:ZSAN) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that the previously announced Notice of Allowance of our patent application titled “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines” has resulted in the issuance of a U.S. patent 9,918,932.

As quoted in the press release:

“We are pleased to have this important expansion of our patent estate for M207,” said John Walker, Chairman and Chief Executive Officer of Zosano. “This issuance supports our intellectual property strategy for our ADAM technology, and specifically M207.  We intend to pursue similar patent coverage for future products that Zosano develops internally, and in future partnerships.”

Zosano’s patent estate additionally includes other granted U.S. and foreign patents and pending patent applications covering our ADAM technology, including our microneedle technology, drug formulations, methods of use and applicators.

Click here to read the full press release.